Walvax Biotechnology Co., Ltd.

300142

CNE100000WN2

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
14.33 ^CNY	+3.54%		+2.43%	-39.05%

Apr. 26	Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024	MT
Apr. 25	Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial	MT

Walvax Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 11, 2023

May 05, 2023 at 03:57 pm EDT

Walvax Biotechnology Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 0.10000000 on A shares for the year 2022. Record date is 10 May 2023. Ex-date is 11 May 2023.

Payment date is 11 May 2023.

Latest news about Walvax Biotechnology Co., Ltd.

Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024	Apr. 26	MT
Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial	Apr. 25	MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
China's drugmakers can't sell mRNA shots but haven't quit yet	Apr. 19	RE
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	Apr. 03	CI
Walvax Biotechnology Co., Ltd.'s Equity Buyback announced on April 5, 2023, has expired with 2,000,000 shares, representing 0.12% for CNY 72.2 million.	Apr. 02	CI
Walvax Biotechnology's 2023 Profit Falls 42%	Apr. 02	MT
Walvax Biotechnology Co., Ltd. Proposes Cash Profit Distribution for 2023	Apr. 01	CI
Walvax Biotechnology Scraps Plan to Issue Convertible Bonds	Apr. 01	MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Walvax Biotechnology Sees Up to 45% Drop in 2023 Profit	Jan. 26	MT
Chinese Shares End Mixed as Stimulus Hopes Fade; Walvax Falls 6% on Downbeat Profit Outlook	Jan. 26	MT
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China	Jan. 10	MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	Jan. 03	CI
Lanvin Group Chief Executive Joann Cheng Steps Down	Dec. 08	MT
Walvax Biotechnology Registers Pneumonia Vaccines in Philippines	Nov. 08	MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Walvax Biotechnology's Unit Gets License to Market Pneumonia Vaccine in Indonesia; Shares Up 3%	23-10-24	MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	23-10-11	CI
Walvax Biotechnology Unit Gets Nod to Carry Out Vaccine's Phase III Trial in Indonesia	23-09-20	MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Walvax Biotechnology's COVID-19 Vaccine Clinical Trial Results Show Efficacy, Safety	23-07-11	MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.	23-07-03	CI
Walvax Biotechnology Chairman, Affiliates Complete Purchase of 101 Million Yuan Shares	23-06-26	MT
Walvax Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 11, 2023	23-05-05	CI

Chart Walvax Biotechnology Co., Ltd.

Duration

Period

More charts

Walvax Biotechnology Co. specialises in the research, development, manufacturing and marketing of human vaccines. Products include vaccines against haemophilus influenzae, meningitis, septicaemia, meningococcal disease, etc.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Walvax Biotechnology Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

14.33 CNY

Average target price

20 CNY

Spread / Average Target

+39.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
WALVAX BIOTECHNOLOGY CO., LTD.	-39.05%	3.16B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B

Biopharmaceuticals